Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
media
posted on 2021-05-26, 15:19 authored by Adis journals on behalf of:, Luís Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, Nikita A. Zolkin, Ivan V. Kuryshev, Alexey N. Petrov, Antonina V. Artemeva, Arina V. Zinkina-Orikhan<p><strong>Article full
text</strong></p>
<p> </p>
<p><br></p>
<p> </p>
<p>The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2021.</p>
<p> </p>
History
Related Materials
- 1.
- 2.
